Enhancers and Super-Enhancers Have an Equivalent Regulatory Role in Embryonic Stem Cells Through Regulation of Single Or Multiple Genes
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Identifying and Mapping Cell-Type-Specific Chromatin PNAS PLUS Programming of Gene Expression
Identifying and mapping cell-type-specific chromatin PNAS PLUS programming of gene expression Troels T. Marstranda and John D. Storeya,b,1 aLewis-Sigler Institute for Integrative Genomics, and bDepartment of Molecular Biology, Princeton University, Princeton, NJ 08544 Edited by Wing Hung Wong, Stanford University, Stanford, CA, and approved January 2, 2014 (received for review July 2, 2013) A problem of substantial interest is to systematically map variation Relating DHS to gene-expression levels across multiple cell in chromatin structure to gene-expression regulation across con- types is challenging because the DHS represents a continuous ditions, environments, or differentiated cell types. We developed variable along the genome not bound to any specific region, and and applied a quantitative framework for determining the exis- the relationship between DHS and gene expression is largely tence, strength, and type of relationship between high-resolution uncharacterized. To exploit variation across cell types and test chromatin structure in terms of DNaseI hypersensitivity and genome- for cell-type-specific relationships between DHS and gene expres- wide gene-expression levels in 20 diverse human cell types. We sion, the measurement units must be placed on a common scale, show that ∼25% of genes show cell-type-specific expression ex- the continuous DHS measure associated to each gene in a well- plained by alterations in chromatin structure. We find that distal defined manner, and all measurements considered simultaneously. regions of chromatin structure (e.g., ±200 kb) capture more genes Moreover, the chromatin and gene-expression relationship may with this relationship than local regions (e.g., ±2.5 kb), yet the local only manifest in a single cell type, making standard measures of regions show a more pronounced effect. -
No Evidence for Transvection in Vivo by a Superenhancer:Promoter Pair
bioRxiv preprint doi: https://doi.org/10.1101/393363; this version posted August 16, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 No evidence for transvection in vivo by a superenhancer:promoter 2 pair integrated into identical open chromatin at the Rosa26 locus 3 4 Keiji Tanimoto1, 2, *, Hitomi Matsuzaki1, 2, Eiichi Okamura3, Aki Ushiki2, Akiyoshi 5 Fukamizu1, 2, and James Douglas Engel4 6 7 1 Faculty of Life and Environmental Sciences, Life Science Center for Survival Dynamics, 8 Tsukuba Advanced Research Alliance (TARA), University of Tsukuba, Tsukuba, Ibaraki 9 305-8577, Japan 10 2 Graduate School of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Ibaraki 11 305-8577, Japan 12 3 Graduate School of Biomedical Sciences, Tokushima University, Tokushima 770-8503, Japan 13 4 Department of Cell and Developmental Biology, University of Michigan, USA 14 15 16 17 * Corresponding author: Faculty of Life and Environmental Sciences, 18 University of Tsukuba, Tennoudai 1-1-1 19 Tsukuba, Ibaraki 305-8577, Japan 20 Phone/Fax: (+81) 29-853-6070 21 E-mail: [email protected] 22 1 bioRxiv preprint doi: https://doi.org/10.1101/393363; this version posted August 16, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. -
Evidence for Differential Alternative Splicing in Blood of Young Boys With
Stamova et al. Molecular Autism 2013, 4:30 http://www.molecularautism.com/content/4/1/30 RESEARCH Open Access Evidence for differential alternative splicing in blood of young boys with autism spectrum disorders Boryana S Stamova1,2,5*, Yingfang Tian1,2,4, Christine W Nordahl1,3, Mark D Shen1,3, Sally Rogers1,3, David G Amaral1,3 and Frank R Sharp1,2 Abstract Background: Since RNA expression differences have been reported in autism spectrum disorder (ASD) for blood and brain, and differential alternative splicing (DAS) has been reported in ASD brains, we determined if there was DAS in blood mRNA of ASD subjects compared to typically developing (TD) controls, as well as in ASD subgroups related to cerebral volume. Methods: RNA from blood was processed on whole genome exon arrays for 2-4–year-old ASD and TD boys. An ANCOVA with age and batch as covariates was used to predict DAS for ALL ASD (n=30), ASD with normal total cerebral volumes (NTCV), and ASD with large total cerebral volumes (LTCV) compared to TD controls (n=20). Results: A total of 53 genes were predicted to have DAS for ALL ASD versus TD, 169 genes for ASD_NTCV versus TD, 1 gene for ASD_LTCV versus TD, and 27 genes for ASD_LTCV versus ASD_NTCV. These differences were significant at P <0.05 after false discovery rate corrections for multiple comparisons (FDR <5% false positives). A number of the genes predicted to have DAS in ASD are known to regulate DAS (SFPQ, SRPK1, SRSF11, SRSF2IP, FUS, LSM14A). In addition, a number of genes with predicted DAS are involved in pathways implicated in previous ASD studies, such as ROS monocyte/macrophage, Natural Killer Cell, mTOR, and NGF signaling. -
CTCF-Dependent Enhancer-Blocking by Alternative Chromatin Loop Formation
CTCF-dependent enhancer-blocking by alternative chromatin loop formation Chunhui Houa, Hui Zhaoa,1, Keiji Tanimotob, and Ann Deana,2 aLaboratory of Cellular and Developmental Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892; and bGraduate School of Life and Environmental Sciences, University of Tsukuba, Tsukuba, 305-8577, Japan Edited by Gary Felsenfeld, National Institutes of Health, Bethesda, MD, and approved November 1, 2008 (received for review August 27, 2008) The mechanism underlying enhancer-blocking by insulators is expressed (14, 15). However, the function of HS5 in vivo is not unclear. We explored the activity of human -globin HS5, the clear. Chromosomal deletion of mouse HS5 had no significant orthologue of the CTCF-dependent chicken HS4 insulator. An extra effect on -globin expression or on silent odorant receptor genes copy of HS5 placed between the -globin locus control region (LCR) located downstream of HS5, indicating that HS5 is not required and downstream genes on a transgene fulfills the classic predic- as an insulator at its endogenous location (16, 17). In contrast, tions for an enhancer-blocker. Ectopic HS5 does not perturb the LCR an ectopic globin gene placed upstream in a human transgenic but blocks gene activation by interfering with RNA pol II, activator globin locus, and separated from the LCR by HS5, failed to be and coactivator recruitment, and epigenetic modification at the activated, although some evidence suggested the blocking varied downstream -globin gene. Underlying these effects, ectopic HS5 in a developmental stage-specific fashion (18, 19). disrupts chromatin loop formation between -globin and the LCR, Earlier studies suggested that human HS5 could function as a and instead forms a new loop with endogenous HS5 that topo- transcriptional enhancer-blocker when placed between the LCR logically isolates the LCR. -
Development and Validation of a One-Step RT-Qpcr
Development and Validation of a One-Step RT-qPCR Assay for Identifying Common Fusion Gene Transcripts Associated with the Prognosis of Mexican Children with B-Lineage Acute Lymphoblastic Leukemia Juan Manuel Mejía-Aranguré ( [email protected] ) IMSS: Instituto Mexicano del Seguro Social https://orcid.org/0000-0003-0949-461X Minerva Mata-Rocha CONACYT: Consejo Nacional de Ciencia y Tecnologia Angelica Rangel-López IMSS: Instituto Mexicano del Seguro Social Juan Carlos Núñez-Enríquez IMSS: Instituto Mexicano del Seguro Social Elva Jiménez-Hernández IMSS: Instituto Mexicano del Seguro Social Blanca Angélica Morales-Castillo IMSS: Instituto Mexicano del Seguro Social Norberto Sánchez-Escobar UABJO Faculty of Medicine: Universidad Autonoma Benito Juarez de Oaxaca Facultad de Medicina Omar Alejandro Sepúlveda-Robles CONACYT: Consejo Nacional de Ciencia y Tecnologia Juan Carlos Bravata-Alcántara Hospital Juárez de México: Hospital Juarez de Mexico Alan Steve Nájera-Cortés Hospital Juárez de México: Hospital Juarez de Mexico María Luisa Pérez-Saldivar IMSS: Instituto Mexicano del Seguro Social Janet Flores-Lujano IMSS: Instituto Mexicano del Seguro Social David Aldebarán Duarte-Rodríguez IMSS: Instituto Mexicano del Seguro Social Norma Angélica Oviedo de Anda IMSS: Instituto Mexicano del Seguro Social Page 1/22 Carmen Alaez Verson INMEGEN: Instituto Nacional de Medicina Genomica Jorge Alfonso Martín-Trejo IMSS: Instituto Mexicano del Seguro Social María de Los Ángeles Del Campo-Martínez IMSS: Instituto Mexicano del Seguro Social José Esteban -
Amlexanox Downregulates S100A6 to Sensitize KMT2A/AFF1-Positive
Published OnlineFirst June 23, 2017; DOI: 10.1158/0008-5472.CAN-16-2974 Cancer Therapeutics, Targets, and Chemical Biology Research Amlexanox Downregulates S100A6 to Sensitize KMT2A/AFF1-Positive Acute Lymphoblastic Leukemia to TNFa Treatment Hayato Tamai1, Hiroki Yamaguchi1, Koichi Miyake2, Miyuki Takatori3, Tomoaki Kitano1, Satoshi Yamanaka1, Syunsuke Yui1, Keiko Fukunaga1, Kazutaka Nakayama1, and Koiti Inokuchi1 Abstract Acute lymphoblastic leukemias (ALL) positive for KMT2A/ to inhibit S100A6 expression in the presence of TNF-a.InKMT2A/ AFF1 (MLL/AF4) translocation, which constitute 60% of all infant AFF1-positive transgenic (Tg) mice, amlexanox enhanced tumor ALL cases, have a poor prognosis even after allogeneic hemato- immunity and lowered the penetrance of leukemia development. poietic stem cell transplantation (allo-HSCT). This poor progno- Similarly, in a NOD/SCID mouse model of human KMT2A/AFF1- sis is due to one of two factors, either resistance to TNFa, which positive ALL, amlexanox broadened GVL responses and extended mediates a graft-versus-leukemia (GVL) response after allo-HSCT, survival. Our findings show how amlexanox degrades the resis- or immune resistance due to upregulated expression of the tance of KMT2A/AFF1-positive ALL to TNFa by downregulating immune escape factor S100A6. Here, we report an immune S100A6 expression, with immediate potential implications for stimulatory effect against KMT2A/AFF1-positive ALL cells by improving clinical management of KMT2A/AFF1-positive ALL. treatment with the anti-allergy drug amlexanox, which we found Cancer Res; 77(16); 1–8. Ó2017 AACR. Introduction involved in the graft-versus-leukemia (GVL) effect, or tumor immunity by upregulation of S100A6 expression followed The most prevalent mixed-lineage leukemia (MLL) rearrange- by interference with the p53–caspase pathway (3). -
Molecular Basis of the Function of Transcriptional Enhancers
cells Review Molecular Basis of the Function of Transcriptional Enhancers 1,2, 1, 1,3, Airat N. Ibragimov y, Oleg V. Bylino y and Yulii V. Shidlovskii * 1 Laboratory of Gene Expression Regulation in Development, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov St., 119334 Moscow, Russia; [email protected] (A.N.I.); [email protected] (O.V.B.) 2 Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov St., 119334 Moscow, Russia 3 I.M. Sechenov First Moscow State Medical University, 8, bldg. 2 Trubetskaya St., 119048 Moscow, Russia * Correspondence: [email protected]; Tel.: +7-4991354096 These authors contributed equally to this study. y Received: 30 May 2020; Accepted: 3 July 2020; Published: 5 July 2020 Abstract: Transcriptional enhancers are major genomic elements that control gene activity in eukaryotes. Recent studies provided deeper insight into the temporal and spatial organization of transcription in the nucleus, the role of non-coding RNAs in the process, and the epigenetic control of gene expression. Thus, multiple molecular details of enhancer functioning were revealed. Here, we describe the recent data and models of molecular organization of enhancer-driven transcription. Keywords: enhancer; promoter; chromatin; transcriptional bursting; transcription factories; enhancer RNA; epigenetic marks 1. Introduction Gene transcription is precisely organized in time and space. The process requires the participation of hundreds of molecules, which form an extensive interaction network. Substantial progress was achieved recently in our understanding of the molecular processes that take place in the cell nucleus (e.g., see [1–9]). -
CNOT2 Antibody A
C 0 2 - t CNOT2 Antibody a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 5 5 Web: [email protected] 9 www.cellsignal.com 6 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source: UniProt ID: Entrez-Gene Id: WB, IP H M R Mk Endogenous 62 Rabbit Q9NZN8 4848 Product Usage Information Application Dilution Western Blotting 1:1000 Immunoprecipitation 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity CNOT2 Antibody recognizes endogenous levels of total CNOT2 protein. Species Reactivity: Human, Mouse, Rat, Monkey Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CNOT2 protein. Antibodies are purified by protein A and peptide affinity chromatography. Background The evolutionarily conserved CCR4-NOT (CNOT) complex regulates mRNA metabolism in eukaryotic cells (1). This regulation occurs at different levels of mRNA synthesis and degradation, including transcription initiation, elongation, deadenylation, and degradation (1). Multiple components, including CNOT1, CNOT2, CNOT3, CNOT4, CNOT6, CNOT6L, CNOT7, CNOT8, CNOT9, and CNOT10 have been identified in this complex (2). In addition, subunit composition of this complex has been shown to vary among different tissues (3). 1. Denis, C.L. and Chen, J. (2003) Prog Nucleic Acid Res Mol Biol 73, 221-50. 2. Lau, N.C. et al. -
Novelty Indicator for Enhanced Prioritization of Predicted Gene Ontology Annotations
IEEE/ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS, VOL. X, NO. X, MONTHXXX 20XX 1 Novelty Indicator for Enhanced Prioritization of Predicted Gene Ontology Annotations Davide Chicco, Fernando Palluzzi, and Marco Masseroli Abstract—Biomolecular controlled annotations have become pivotal in computational biology, because they allow scientists to analyze large amounts of biological data to better understand their test results, and to infer new knowledge. Yet, biomolecular annotation databases are incomplete by definition, like our knowledge of biology, and may contain errors and inconsistent information. In this context, machine-learning algorithms able to predict and prioritize new biomolecular annotations are both effective and efficient, especially if compared with the time-consuming trials of biological validation. To limit the possibility that these techniques predict obvious and trivial high-level features, and to help prioritizing their results, we introduce here a new element that can improve the accuracy and relevance of the results of an annotation prediction and prioritization pipeline. We propose a novelty indicator able to state the level of ”newness” (or ”originality”) of the annotations predicted for a specific gene to Gene Ontology terms, and to help prioritizing the most novel and interesting annotations predicted. We performed a thorough biological functional analysis of the prioritized annotations predicted with high accuracy by using this indicator and our previously proposed prediction algorithms. The relevance -
BRG1 Requirement for Long-Range Interaction of a Locus Control Region with a Downstream Promoter
BRG1 requirement for long-range interaction of a locus control region with a downstream promoter Shin-Il Kima, Scott J. Bultmanb, Christine M. Kieferc, Ann Deanc, and Emery H. Bresnicka,1 aDepartment of Pharmacology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706; bDepartment of Genetics, University of North Carolina, Chapel Hill, NC 27599; and cLaboratory of Cellular and Developmental Biology, National Institutes of Diabetes and Digestive and Kidney Disorders, National Institutes of Health, Bethesda, MD 20892 Edited by Mark T. Groudine, Fred Hutchinson Cancer Research Center, Seattle, WA, and approved December 4, 2008 (received for review July 2, 2008) The dynamic packaging of DNA into chromatin is a fundamental step generation of conditional knockouts or hypomorphic alleles rep- in the control of diverse nuclear processes. Whereas certain transcrip- resents a powerful strategy for conducting mechanistic analyses. A tion factors and chromosomal components promote the formation of mouse strain was isolated containing an ethyl-nitrosourea-induced higher-order chromatin loops, the co-regulator machinery mediating hypomorphic Brg1 mutation (26). Although this mutation resides loop assembly and disassembly is unknown. Using mice bearing a within the ATPase domain, ATPase activity appears to be unal- hypomorphic allele of the BRG1 chromatin remodeler, we demon- tered. Brg1null/ENU1 mice (Brg1-mutant) are anemic and die by strate that the Brg1 mutation abrogated a cell type-specific loop embryonic day 14.5. -globin transcription is severely reduced in between the -globin locus control region and the downstream Brg1-mutant fetal livers, even though factors occupy the LCR and major promoter, despite trans-acting factor occupancy at both sites. -
A KMT2A-AFF1 Gene Regulatory Network Highlights the Role of Core Transcription Factors and Reveals the Regulatory Logic of Key Downstream Target Genes
Downloaded from genome.cshlp.org on October 7, 2021 - Published by Cold Spring Harbor Laboratory Press Research A KMT2A-AFF1 gene regulatory network highlights the role of core transcription factors and reveals the regulatory logic of key downstream target genes Joe R. Harman,1,7 Ross Thorne,1,7 Max Jamilly,2 Marta Tapia,1,8 Nicholas T. Crump,1 Siobhan Rice,1,3 Ryan Beveridge,1,4 Edward Morrissey,5 Marella F.T.R. de Bruijn,1 Irene Roberts,3,6 Anindita Roy,3,6 Tudor A. Fulga,2,9 and Thomas A. Milne1,6 1MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, United Kingdom; 2MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, United Kingdom; 3MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 9DS, United Kingdom; 4Virus Screening Facility, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, United Kingdom; 5Center for Computational Biology, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; 6NIHR Oxford Biomedical Research Centre Haematology Theme, University of Oxford, Oxford, OX3 9DS, United Kingdom Regulatory interactions mediated by transcription factors (TFs) make up complex networks that control cellular behavior. Fully understanding these gene regulatory networks (GRNs) offers greater insight into the consequences of disease-causing perturbations than can be achieved by studying single TF binding events in isolation. Chromosomal translocations of the lysine methyltransferase 2A (KMT2A) gene produce KMT2A fusion proteins such as KMT2A-AFF1 (previously MLL-AF4), caus- ing poor prognosis acute lymphoblastic leukemias (ALLs) that sometimes relapse as acute myeloid leukemias (AMLs). -
The -Globin Locus Control Region
Downloaded from genesdev.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press The -globin locus control region (LCR) functions primarily by enhancing the transition from transcription initiation to elongation Tomoyuki Sawado,1 Jessica Halow,1 M.A. Bender,2,3 and Mark Groudine1,4,5 1Division of Basic Sciences, 2Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA; 3Department of Pediatrics, 4Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington 98104, USA To investigate the molecular basis of -globin gene activation, we analyzed factor recruitment and histone modification at the adult -globin gene in wild-type (WT)/locus control region knockout (⌬LCR) heterozygous mice and in murine erythroleukemia (MEL) cells. Although histone acetylation and methylation (Lys 4) are high before and after MEL differentiation, recruitment of the erythroid-specific activator NF-E2 to the promoter and preinitiation complex (PIC) assembly occur only after differentiation. We reported previously that targeted deletion of the LCR reduces -globin gene expression to 1%–4% of WT without affecting promoter histone acetylation. Here, we report that NF-E2 is recruited equally efficiently to the adult -globin promoters of the ⌬LCR and WT alleles. Moreover, the LCR deletion reduces PIC assembly only twofold, but has a dramatic effect on Ser 5 phosphorylation of RNA polymerase II and transcriptional elongation. Our results suggest at least three distinct stages in -globin gene activation: (1) an LCR-independent chromatin opening stage prior to NF-E2 recruitment to the promoter and PIC assembly; (2) an intermediate stage in which NF-E2 binding (LCR-independent) and PIC assembly (partially LCR-dependent) occur; and (3) an LCR-dependent fully active stage characterized by efficient pol II elongation.